Anteris Technologies will reveal the first 30-day clinical and hemodynamic outcomes for its medium-size DurAVR Transcatheter Heart Valve (THV) at the TCT 2026 conference. The data comes from the ongoing EMBARK study involving over 130 patients treated since 2021. This presentation highlights the innovative biomimetic design of the DurAVR valve, which aims to replicate natural aortic valve function and improve treatment for severe aortic stenosis. Further insights will be shared in sessions focusing on emerging TAVR technologies, signaling potential advancements in heart valve replacement therapies.
Anteris Technologies' upcoming data release on its medium-size DurAVR THV provides context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 27, 2026 17:02 WIB: out of 150 priced US health-sector stocks, 60 rose and 78 fell. Notable movers include AMRX at USD 20.50 with a -2.47% change and a typical hold time of 18 days, ENVB at USD 1.41 up 2.17% with a 15-day hold, and XRAY at USD 9.42 up 2.17%, with 100% buy orders and a 73-day typical hold time.
Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...
eSoftware Associates advises defense contractors to carefully map controlled unclassified information (CUI) access permissions before licensing Microsoft 365 Copilot in the GCC High cloud environment. Moving to GCC High does not automatically grant c...
Nautilus Biotechnology announced its Q3 2026 financial results, reporting $0.2 million in revenue mainly from grants and early access services, and a net loss of $15.6 million. The company highlighted progress in its proteome analysis platform, inclu...
Eviden, part of Atos Group, has introduced ASTRA-LAS, a tactical decision-support solution designed to aid naval officers in complex maritime environments. The system uses operational data and AI to enhance situational awareness, reduce cognitive loa...
Eviden, part of Atos Group, has introduced ASTRA-LAS, a new AI-powered tactical assistant designed to support naval operations by providing enhanced visualizations, automated analyses, and mission-specific recommendations. This system helps naval off...
